Bevacizumab in combination with paclitaxel for patients who have not received chemotherapy for metastatic HER2 negative breast cancer received the US-accelerated approval in 2008 and was withdrawn in 2011 due to the failure to improve OS, though it improved the PFS [29–31]. This evidence concerns the gene ERBB2 and breast carcinoma.